Meanwhile, there was bad blood between cell therapy players and their investors.
Duelling datasets on the companies’ rival menin inhibitors show each to have weaknesses and strengths.
In oncology settings outside multiple myeloma investors have picked two early winners.
The early movers could point to a disappointing meeting.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.